Advance Auto Parts Earnings Show Strong Quarter

Advance Auto Parts earnings showed stronger comps and margin recovery with $2.6 billion sales, reinforcing full-year guidance and prompting repositioning.

May 21, 2026·2 min read
View all news articles
Flat filled vector of an auto part morphing into a hub representing Advance Auto Parts earnings and $2.6 billion sales.

KEY TAKEAWAYS

  • Net sales were $2.6 billion and comparable-store sales rose 3.5%.
  • Gross margin expanded to 45.1% and operating income turned positive at $69 million.
  • Company reaffirmed full-year guidance and set adjusted diluted EPS range of $2.40-$3.10.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Advance Auto Parts (AAP) said in its May 21, 2026, earnings release that first-quarter results showed higher comparable-store sales and a return to operating profit, and the company reaffirmed full-year guidance.

Quarterly Results and Margins

The company reported net sales of $2.6 billion for the quarter ended April 25, 2026. Comparable-store sales rose 3.5%, marking the strongest quarterly growth in five years. Gross profit increased to $1.2 billion, or 45.1% of net sales, up from $1.1 billion, or 42.9%, a year earlier.

Operating income turned positive at $69 million, reversing a $131 million loss in the prior year. On an adjusted basis, operating income was $99 million, or 3.8% of net sales, compared with an adjusted operating loss of $8 million a year earlier. Diluted earnings per share were $0.39, while adjusted diluted EPS rose to $0.77, compared with a loss of $0.22 per share in the first quarter of 2025.

The company declared a quarterly dividend of $0.25 per share.

Guidance and Capital Allocation

Advance Auto Parts reaffirmed full-year 2026 guidance, projecting net sales between $8.5 billion and $8.6 billion and comparable-store sales growth of 1.0% to 2.0%. The company expects an adjusted operating-income margin of 3.8% to 4.5% and adjusted diluted EPS of $2.40 to $3.10. Capital expenditures are forecast at roughly $300 million, with free cash flow near $100 million.

The combination of rising comparable-store sales, improved gross margins, and a swing to operating profit, alongside reaffirmed guidance and the dividend, signals that the company’s recovery is translating into profit leverage and supports its near-term capital-allocation strategy.

“Comparable store sales increased 3.5%,” the company said in its release.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Urban Outfitters Q1 Earnings Surge on Nuuly Growth

Urban Outfitters Q1 Earnings Surge on Nuuly Growth

Urban Outfitters Q1 earnings showed record sales and surging Nuuly subscriptions, prompting analyst upgrades and lifting retail share positioning.

Deere Q2 Earnings Beat Despite Weak Farm Demand

Deere Q2 Earnings Beat Despite Weak Farm Demand

Deere Q2 earnings topped estimates as pricing and construction growth offset weak large-farm demand, giving traders a resilience angle for positioning.

Ralph Lauren Earnings Rise on China Strength

Ralph Lauren Earnings Rise on China Strength

Ralph Lauren earnings beat estimates as the company cited China demand and issued fiscal 2027 outlook, refocusing traders on guidance and margin risk.

Parker Hannifin Acquires CIRCOR Aerospace for $2.55 Billion

Parker Hannifin Acquires CIRCOR Aerospace for $2.55 Billion

Parker Hannifin Acquires CIRCOR Aerospace in a $2.6 billion cash deal that includes $75 million tax NPV and 10.0% synergies, prompting investor repricing.

NIO Q1 2026 Results: Deliveries Soar, Margins Scrutinized

NIO Q1 2026 Results: Deliveries Soar, Margins Scrutinized

NIO Q1 2026 Results show deliveries and revenue surged while a sequential vehicle-margin dip and input-cost headwinds left traders wary and lifted IV.

Eli Lilly Retatrutide Results Propel Obesity Push

Eli Lilly Retatrutide Results Propel Obesity Push

Eli Lilly retatrutide results show topline weight loss that supports Lilly's regulatory plans and likely reshapes obesity franchise expectations.